Home Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines
 

Keywords :   


Merck Welcomes Independent Review of the Safety Profile of JANUVIA (sitagliptin) and Other Diabetes Medicines

2013-06-12 14:00:00| Merck.com - Product News

Dateline City:  WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued the following statement regarding this week's NIDDK-NCI Workshop and the American Diabetes Associations (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors such as JANUVIA (sitagliptin). Language:  English Contact HTML:  MerckMedia:Pam Eisele(267) 664-0282orKim Hamilton(908) 391-0131orInvestor:Carol Ferguson(908) 423-4465 Ticker Slug:  Ticker: MRK Exchange: NYSE read more

Tags: other profile review safety

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Vodafone-Three merger could get green light, watchdog says
05.11Altice USA residential video RGUs down 77,000 in 3Q 2024
05.11Shoppers warned over luxury advent calendar scams
05.11Durable Floor Coating from HMG Paints Transforms FC United\'s SMRE Bar
05.11Teknos Poland Honored by Farby i Lakiery
05.11Xumo teams up with Target to offer Hisense Xumo TVs
05.11KT launches 8K AI-powered IPTV set-top box
05.11Tropical Storm Rafael Graphics
More »